Mycophenolate mofetil for corticosteroid-resistant immune-related cystitis associated with tislelizumab: a case report
Abstract
Immune-related cystitis is an uncommon immune-related adverse event (irAE) linked to immune checkpoint inhibitors (ICIs), and managing cases refractory to corticosteroids remains clinically challenging due to the lack of standardized treatment guidelines. We describe a 56-year-old male with extensive-stage small-cell lung cancer who developed corticosteroid-refractory immune-related cystitis following fourth-line therapy with Tislelizumab combined with irinotecan and anlotinib. The patient presented with frequent urination, urgent urination, and dysuria. Urine cultures were negative, and antibiotic treatment failed to alleviate symptoms, leading to a diagnosis of immune-related cystitis (CTCAE grade 3). Initial treatment with methylprednisolone 80 mg/day provided symptom relief, but symptoms recurred when the dose was tapered. Even after escalating the dose to 40 mg/day, symptoms persisted, confirming corticosteroid refractoriness. Combination therapy with prednisone 30 mg/day and mycophenolate mofetil (MMF) 1 g once daily resulted in symptom resolution within 1 week, with normalization of urine routine findings by 8 weeks. Corticosteroids were successfully tapered off without recurrence. This is the first reported case of successful MMF use for ICI-related cystitis, offering a new therapeutic option for corticosteroid-refractory cases. We also discuss considerations for ICI reinitiation to provide a clinical reference.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.